Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Vertex Pharmaceuticals Announced Advancements Across Its Suzetrigine Pain Program For Acute And Neuropathic Pain

Author: Benzinga Newsdesk | April 18, 2024 08:05am

Rolling submission for suzetrigine moderate-to-severe acute pain NDA granted by FDA; first module submitted and on track to complete filing this quarter.
Successful completion of end-of-phase 2 FDA meeting for pain associated with diabetic peripheral neuropathy (DPN); Phase 3 program to initiate in 2H 2024.
Breakthrough Therapy designation for pain associated with DPN granted by FDA.
Enrollment of Phase 2 study in patients with painful lumbosacral radiculopathy on track to complete by end of year.

Posted In: VRTX